vs

Side-by-side financial comparison of Flywire Corp (FLYW) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $157.5M, roughly 1.3× Flywire Corp). Flywire Corp runs the higher net margin — 0.0% vs -62.0%, a 62.0% gap on every dollar of revenue. On growth, Flywire Corp posted the faster year-over-year revenue change (34.0% vs 25.9%). Flywire Corp produced more free cash flow last quarter ($4.5M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 17.5%).

Flywire Corp is a global payment and receivables solutions provider serving core verticals including education, healthcare, travel, and B2B commerce. It offers secure cross-border payment processing, currency conversion, and workflow tools for organizations and payers worldwide.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

FLYW vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.3× larger
RARE
$207.3M
$157.5M
FLYW
Growing faster (revenue YoY)
FLYW
FLYW
+8.1% gap
FLYW
34.0%
25.9%
RARE
Higher net margin
FLYW
FLYW
62.0% more per $
FLYW
0.0%
-62.0%
RARE
More free cash flow
FLYW
FLYW
$105.3M more FCF
FLYW
$4.5M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
17.5%
FLYW

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FLYW
FLYW
RARE
RARE
Revenue
$157.5M
$207.3M
Net Profit
$33.0K
$-128.6M
Gross Margin
Operating Margin
-0.6%
-54.7%
Net Margin
0.0%
-62.0%
Revenue YoY
34.0%
25.9%
Net Profit YoY
100.2%
3.5%
EPS (diluted)
$0.01
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FLYW
FLYW
RARE
RARE
Q4 25
$157.5M
$207.3M
Q3 25
$200.1M
$159.9M
Q2 25
$131.9M
$166.5M
Q1 25
$133.5M
$139.3M
Q4 24
$117.5M
$164.6M
Q3 24
$156.8M
$139.5M
Q2 24
$103.7M
$147.0M
Q1 24
$114.1M
$108.8M
Net Profit
FLYW
FLYW
RARE
RARE
Q4 25
$33.0K
$-128.6M
Q3 25
$29.6M
$-180.4M
Q2 25
$-12.0M
$-115.0M
Q1 25
$-4.2M
$-151.1M
Q4 24
$-15.9M
$-133.2M
Q3 24
$38.9M
$-133.5M
Q2 24
$-13.9M
$-131.6M
Q1 24
$-6.2M
$-170.7M
Operating Margin
FLYW
FLYW
RARE
RARE
Q4 25
-0.6%
-54.7%
Q3 25
16.1%
-106.9%
Q2 25
-6.8%
-64.8%
Q1 25
-8.2%
-102.6%
Q4 24
-4.9%
-74.3%
Q3 24
12.9%
-94.6%
Q2 24
-15.2%
-79.1%
Q1 24
-5.2%
-151.9%
Net Margin
FLYW
FLYW
RARE
RARE
Q4 25
0.0%
-62.0%
Q3 25
14.8%
-112.8%
Q2 25
-9.1%
-69.0%
Q1 25
-3.1%
-108.5%
Q4 24
-13.5%
-80.9%
Q3 24
24.8%
-95.7%
Q2 24
-13.4%
-89.5%
Q1 24
-5.4%
-156.8%
EPS (diluted)
FLYW
FLYW
RARE
RARE
Q4 25
$0.01
$-1.28
Q3 25
$0.23
$-1.81
Q2 25
$-0.10
$-1.17
Q1 25
$-0.03
$-1.57
Q4 24
$-0.12
$-1.34
Q3 24
$0.30
$-1.40
Q2 24
$-0.11
$-1.52
Q1 24
$-0.05
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FLYW
FLYW
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$355.0M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$835.2M
$-80.0M
Total Assets
$1.3B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FLYW
FLYW
RARE
RARE
Q4 25
$355.0M
$421.0M
Q3 25
$377.3M
$202.5M
Q2 25
$274.2M
$176.3M
Q1 25
$255.3M
$127.1M
Q4 24
$611.1M
$174.0M
Q3 24
$681.1M
$150.6M
Q2 24
$571.0M
$480.7M
Q1 24
$619.0M
$112.3M
Total Debt
FLYW
FLYW
RARE
RARE
Q4 25
Q3 25
$15.0M
Q2 25
$60.0M
Q1 25
$60.0M
Q4 24
$0
Q3 24
Q2 24
Q1 24
Stockholders' Equity
FLYW
FLYW
RARE
RARE
Q4 25
$835.2M
$-80.0M
Q3 25
$829.1M
$9.2M
Q2 25
$792.4M
$151.3M
Q1 25
$784.3M
$144.2M
Q4 24
$814.8M
$255.0M
Q3 24
$843.2M
$346.8M
Q2 24
$802.6M
$432.4M
Q1 24
$-797.0M
$140.3M
Total Assets
FLYW
FLYW
RARE
RARE
Q4 25
$1.3B
$1.5B
Q3 25
$1.3B
$1.2B
Q2 25
$1.1B
$1.3B
Q1 25
$1.1B
$1.3B
Q4 24
$1.1B
$1.5B
Q3 24
$1.2B
$1.5B
Q2 24
$998.7M
$1.6B
Q1 24
$998.7M
$1.3B
Debt / Equity
FLYW
FLYW
RARE
RARE
Q4 25
Q3 25
0.02×
Q2 25
0.08×
Q1 25
0.08×
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FLYW
FLYW
RARE
RARE
Operating Cash FlowLast quarter
$4.9M
$-99.8M
Free Cash FlowOCF − Capex
$4.5M
$-100.8M
FCF MarginFCF / Revenue
2.9%
-48.6%
Capex IntensityCapex / Revenue
0.2%
0.5%
Cash ConversionOCF / Net Profit
148.06×
TTM Free Cash FlowTrailing 4 quarters
$98.8M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FLYW
FLYW
RARE
RARE
Q4 25
$4.9M
$-99.8M
Q3 25
$150.1M
$-91.4M
Q2 25
$24.1M
$-108.3M
Q1 25
$-78.9M
$-166.5M
Q4 24
$-28.6M
$-79.3M
Q3 24
$184.6M
$-67.0M
Q2 24
$-19.3M
$-77.0M
Q1 24
$-38.1M
$-190.7M
Free Cash Flow
FLYW
FLYW
RARE
RARE
Q4 25
$4.5M
$-100.8M
Q3 25
$149.9M
$-92.7M
Q2 25
$23.5M
$-110.7M
Q1 25
$-79.1M
$-167.8M
Q4 24
$-28.7M
$-79.5M
Q3 24
$184.4M
$-68.6M
Q2 24
$-19.7M
$-79.0M
Q1 24
$-38.3M
$-193.9M
FCF Margin
FLYW
FLYW
RARE
RARE
Q4 25
2.9%
-48.6%
Q3 25
74.9%
-58.0%
Q2 25
17.8%
-66.5%
Q1 25
-59.3%
-120.5%
Q4 24
-24.4%
-48.3%
Q3 24
117.6%
-49.2%
Q2 24
-19.0%
-53.7%
Q1 24
-33.6%
-178.2%
Capex Intensity
FLYW
FLYW
RARE
RARE
Q4 25
0.2%
0.5%
Q3 25
0.1%
0.8%
Q2 25
0.4%
1.5%
Q1 25
0.1%
1.0%
Q4 24
0.1%
0.1%
Q3 24
0.1%
1.2%
Q2 24
0.3%
1.4%
Q1 24
0.2%
3.0%
Cash Conversion
FLYW
FLYW
RARE
RARE
Q4 25
148.06×
Q3 25
5.07×
Q2 25
Q1 25
Q4 24
Q3 24
4.75×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FLYW
FLYW

Transactions$126.4M80%
Platform And Other Revenues$31.1M20%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons